2026-05-02T17:10:45Zhttps://repository.ucc.edu.co/server/oai/request

oai:repository.ucc.edu.co:20.500.12494/159782024-08-11T03:42:07Zcom_20.500.12494_8col_20.500.12494_25

Zapata Builes, Wildeman Hernández López, Juan Carlos Lizdany, Florez 9 2020-01-16T13:43:08Z 2020-01-16T13:43:08Z 2018-10-17 16643224 10.3389/fimmu.2018.02290 https://hdl.handle.net/20.500.12494/15978 Flórez-Álvarez L, Hernandez JC and Zapata W (2018) NK Cells in HIV-1 Infection: From Basic Science to Vaccine Strategies. Front. Immunol. 9:2290. doi: 10.3389/fimmu.2018.02290 NK cells play a key role in immune response against HIV infection. These cells can destroy infected cells and contribute to adequate and strong adaptive immune responses, by acting on dendritic, T, B, and even epithelial cells. Increased NK cell activity reflected by higher cytotoxic capacity, IFN-g and chemokines (CCL3, CCL4, and CCL5) production, has been associated with resistance to HIV infection and delayed AIDS progression, demonstrating the importance of these cells in the antiviral response. Recently, a subpopulation of NK cells with adaptive characteristics has been described and associated with lower HIV viremia and control of infection. These evidences, together with some degree of protection shown in vaccine trials based on boosting NK cell activity, suggest that these cells can be a feasible option for new treatment and vaccination strategies to overcome limitations that, classical vaccination approaches, might have for this virus. This review is focus on the NK cells role during the immune response against HIV, including all the effector mechanisms associated to these cells; in addition, changes including phenotypic, functional and frequency modifications during HIV infection will be pointed, highlighting opportunities to vaccine development based in NK cells effector functions. NK cells play a key role in immune response against HIV infection. These cells can destroy infected cells and contribute to adequate and strong adaptive immune responses, by acting on dendritic, T, B, and even epithelial cells. Increased NK cell activity reflected by higher cytotoxic capacity, IFN-g and chemokines (CCL3, CCL4, and CCL5) production, has been associated with resistance to HIV infection and delayed AIDS progression, demonstrating the importance of these cells in the antiviral response. Recently, a subpopulation of NK cells with adaptive characteristics has been described and associated with lower HIV viremia and control of infection. These evidences, together with some degree of protection shown in vaccine trials based on boosting NK cell activity, suggest that these cells can be a feasible option for new treatment and vaccination strategies to overcome limitations that, classical vaccination approaches, might have for this virus. This review is focus on the NK cells role during the immune response against HIV, including all the effector mechanisms associated to these cells; in addition, changes including phenotypic, functional and frequency modifications during HIV infection will be pointed, highlighting opportunities to vaccine development based in NK cells effector functions. https://scienti.minciencias.gov.co/cvlac/EnProdArticulo/query.do?cod_producto=73&cod_rh=0000157775 https://orcid.org/0000-0002-7351-8738 COL0112548 wildeman.zapatab@campusucc.edu.co https://scholar.google.com.co/citations?hl=en&user=VLZxl1UAAAAJ 13 Universidad Cooperativa de Colombia, Facultad de Ciencias de la Salud, Medicina, Medellín y Envigado Medicina Medellín https://www.frontiersin.org/articles/10.3389/fimmu.2018.02290/full Frontiers in Immunology 1. Montaldo E, Del Zotto G, Della Chiesa M, Mingari MC, Moretta A, De Maria A, et al. Human NK cell receptors/markers: a tool to analyze NK cell development, subsets and function. Cytom A (2013) 83:702–13. doi: 10.1002/cyto.a.22302 2. Fauriat C, Long EO, Ljunggren HG, Bryceson YT. Regulation of human NKcell cytokine and chemokine production by target cell recognition. Blood (2010) 115:2167–76. doi: 10.1182/blood-2009-08-238469 3. Roda JM, Parihar R, Magro C, Nuovo GJ, Tridandapani S, Carson WE. Natural killer cells produce T cell–recruiting chemokines in response to antibody-coated tumor cells. Cancer Res. (2006) 66:517–26. doi: 10.1158/0008-5472.CAN-05-2429 4. Herberman RB, NunnME, Lavrin DH. Natural cytotoxic reactivity of mouse lymphoid cells against syngeneic acid allogeneic tumors. I. Distribution of reactivity and specificity. Int J Cancer (1975) 16:216–29. 5. Bukowski JF, Woda BA, Habu S, Okumura K, Welsh RM. Natural killer cell depletion enhances virus synthesis and virus-induced hepatitis in vivo. J Immunol. (1983) 131:1531–8. 6. Lee SH, Miyagi T, Biron CA. Keeping NK cells in highly regulated antiviral warfare. Trends Immunol. (2007) 28:252–9. doi: 10.1016/j.it.2007.04.001 7. Raulet DH. Roles of the NKG2D immunoreceptor and its ligands. Nat Rev Immunol. (2003) 3:781–90. doi: 10.1038/nri1199 8. Lanier LL. Evolutionary struggles between NK cells and viruses. Nat Rev Immunol. (2008) 8:259–68. doi: 10.1038/nri2276 9. Khakoo SI, Carrington M. KIR and disease: a model system or system of models? Immunol Rev. (2006) 214:186–201. doi: 10.1111/j.1600-065X.2006.00459.x 10. Jamieson AM, Diefenbach A, McMahon CW, Xiong N, Carlyle JR, Raulet DH. The role of the NKG2D immunoreceptor in immune cell activation and natural killing. Immunity (2002) 17:19–29. doi: 10.1016/S1074-7613(02)00333-3 11. Sivori S, Falco M, Chiesa MD, Carlomagno S, Vitale M, Moretta L, et al. CpG and double-stranded RNA trigger human NK cells by Tolllike receptors: Induction of cytokine release and cytotoxicity against tumors and dendritic cells. Proc Natl Acad Sci USA. (2004) 101:10116–21. doi: 10.1073/pnas.0403744101 12. Diefenbach A, Jamieson AM, Liu SD, Shastri N, Raulet DH. Ligands for the murine NKG2D receptor: expression by tumor cells and activation of NK cells and macrophages. Nat Immunol. (2000) 1:119–26. doi: 10.1038/77793 13. Salih HR, Antropius H, Gieseke F, Lutz SZ, Kanz L, Rammensee HG, et al. Functional expression and release of ligands for the activating immunoreceptor NKG2D in leukemia. Blood (2003) 102:1389–96. doi: 10.1182/blood-2003-01-0019 14. Watson FS, Spendlove I, Madjd Z, McGilvray R, Green AR, Ellis IO, et al. Expression of the stress-related MHC class I chain-related protein MICA is an indicator of good prognosis in colorectal cancer patients. Int J Cancer (2006) 118:1445–52. doi: 10.1002/ijc.21510 15. Robbins SH, Bessou G, Cornillon A, Zucchini N, Rupp B, Ruzsics Z,et al. Natural killer cells promote early CD8 T cell responses against cytomegalovirus. PLoS Pathog. (2007) 3:e123. doi: 10.1371/journal.ppat.0030123 16. Crome SQ, Lang PA, Lang KS, Ohashi PS. Natural killer cells regulate diverse T cell responses Trends Immunol. (2013) 34:342–9. doi: 10.1016/j.it.2013. 03.002 17. Campbell KS, Hasegawa J. Natural killer cell biology: an update and future directions. J Allergy Clin Immunol. (2013) 132:536–44. doi: 10.1016/j.jaci.2013.07.006 18. Quillay H, El Costa H, Durie M, Marlin R, Cannou C, Madec Y, et al. NK cells control HIV-1 infection of macrophages through soluble factors and cellular contacts in the human decidua. Retrovirology (2016) 13:39. doi: 10.1186/s12977-016-0271-z 19. Quaranta MG, Napolitano A, Sanchez M, Giordani L, Mattioli B, Viora M. HIV-1 Nef impairs the dynamic of DC/NK crosstalk: different outcome of CD56(dim) and CD56(bright) NK cell subsets. FASEB J. (2007) 21:2323–34. doi: 10.1096/fj.06-7883com 20. Rydyznski C, Daniels KA, Karmele EP, Brooks TR, Mahl SE, Moran MT, et al. Generation of cellular immune memory and B-cell immunity is impaired by natural killer cells. Nat Commun. (2015) 6:6375. doi: 10.1038/ ncomms7375 21. Horton RE,McLaren PJ, Fowke K, Kimani J, Ball TB. Cohorts for the Study of HIV-1–exposed but uninfected individuals: benefits and limitations. J Infect Dis. (2010) 202:S377–81. doi: 10.1086/655971 22. Johansson SE, Rollman E, Chung AW, Center RJ, Hejdeman B, Stratov I, et al. NK cell function and antibodies mediating ADCC in HIV-1- infected viremic and controller patients. Viral Immunol. (2011) 24:359–68. doi: 10.1089/vim.2011.0025 23. Taborda NA, Hernández JC, Lajoie J, Juno JA, Kimani J, Rugeles MT, et al. Short communication: low expression of activation and inhibitory molecules on NK cells and CD4(+) T cells is associated with viral control. AIDS Res Hum Retroviruses. (2015) 31:636–40. doi: 10.1089/AID. 2014.0325 24. Lohman-Payne B, Slyker JA, Moore S, Maleche-Obimbo E, Wamalwa DC, Richardson BA, et al. Breast milk cellular HIV-specific interferon g responses are associated with protection from peripartum HIV transmission. AIDS (2012) 26:2007–16. doi: 10.1097/QAD.0b013e328 359b7e0 25. Scott-Algara D, Truong LX, Versmisse P, David A, Luong TT, Nguyen VN,et al. Cutting edge: increased NK cell activity in HIV-1-exposed but uninfected Vietnamese intravascular drug users. J Immunol. (2003) 171:5663–7. doi: 10.4049/jimmunol.171.11.5663 26. Montoya CJ, Velilla PA, Chougnet C, Landay AL, Rugeles MT. Increased IFN-gamma production by NK and CD3+/CD56+ cells in sexually HIV- 1-exposed but uninfected individuals. Clin Immunol. (2006) 120:138–46. doi: 10.1016/j.clim.2006.02.008 27. Alter G, Altfeld M. Mutiny or scrutiny: NK cell modulation of DC function in HIV-1 infection. Trends Immunol. (2011) 32:219–24. doi: 10.1016/j.it.2011.02.003 28. Osborn L, Kunkel S, Nabel GJ. Tumor necrosis factor alpha and interleukin 1 stimulate the human immunodeficiency virus enhancer by activation of the nuclear factor kappa B. Proc Natl Acad Sci USA. (1989) 86:2336–40. 29. Wada NI, Jacobson LP, Margolick JB, Breen EC, Macatangay B, Penugonda S,et al. The effect of HAART-induced HIV suppression on circulating markers of inflammation and immune activation. AIDS (2015) 29:463–71. doi: 10.1097/QAD.0000000000000545 30. Kumar A, Abbas W, Herbein G. TNF and TNF receptor superfamily members in HIV infection: new cellular targets for therapy? Mediators Inflamm. (2013) 2013:484378. doi: 10.1155/2013/ 484378 31. Gallitano SM, McDermott L, Brar K, Lowenstein E. Use of tumor necrosis factor (TNF) inhibitors in patients with HIV/AIDS. J Am Acad Dermatol. (2016) 74:974–80. doi: 10.1016/j.jaad.2015.11.043 32. Roff SR, Noon-Song EN, Yamamoto JK, Johnson HM. The significance of interferon-g in HIV-1 pathogenesis, therapy, and prophylaxis. Front Immunol. (2014) 4:498. doi: 10.3389/fimmu.2013.00498 33. Oliva A, Kinter AL, Vaccarezza M, Rubbert A, Catanzaro A, Moir S, et al. Natural killer cells from human immunodeficiency virus (HIV)- infected individuals are an important source of CC-chemokines and suppress HIV-1 entry and replication in vitro. J Clin Invest. (1998) 102:223–31. doi: 10.1172/JCI2323 34. WalkerWE, Kurscheid S, Joshi S, Lopez CA, Goh G, ChoiM, et al. Increased levels of macrophage inflammatory proteins result in resistance to R5- tropic HIV-1 in a subset of elite controllers. J Virol. (2015) 89:5502–14. doi: 10.1128/jvi.00118-15 35. Vega JA, Villegas-Ospina S, Aguilar-Jiménez W, Rugeles MT, Bedoya G, ZapataW, et al. Haplotypes in CCR5-CCR2, CCL3, and CCL5 are associated with natural resistance to HIV-1 infection in a Colombian cohort. Biomédica (2017) 37:267–73. doi: 10.7705/biomedica.v37i3.3237 36. Zapata W, Aguilar-Jiménez W, Pineda-Trujillo N, Rojas W, Estrada H, Rugeles MT. Influence of CCR5 and CCR2 genetic variants in the resistance/susceptibility to HIV in serodiscordant couples from Colombia. AIDS Res Hum Retroviruses. (2013) 29:1594–603. doi: 10.1089/aid. 2012.0299 37. Cella M, Fuchs A, Vermi W, Facchetti F, Otero KJ, Lennerz KM, et al. A human natural killer cell subset provides an innate source of IL-22 for mucosal immunity. Nature (2009) 457:722–5. doi: 10.1038/nature07537 38. Zenewicz LA, Flavell RA. Recent advances in IL-22 biology. Int Immunol. (2011) 23:159–63. doi: 10.1093/intimm/dxr001 39. Xu X, Weiss ID, Zhang HH, Singh SP, Wynn TA, Wilson MS, et al. Conventional NK cells can produce IL-22 and promote host defense in Klebsiella pneumoniae Pneumonia. J Immunol. (2014) 192:1778–86. doi: 10.4049/jimmunol.1300039 40. Colonna M. Interleukin-22-producing natural killer cells and lymphoid tissue inducer-like cells in mucosal immunity. Immunity (2009) 31:15–23. doi: 10.1016/j.immuni.2009.06.008 41. Wolk K, Kunz S, Witte E, Friedrich M, Asadullah K, Sabat R. IL-22 increases the innate immunity of tissues. Immunity (2004) 21:241–54. doi: 10.1016/j.immuni.2004.07.007 42. Wolk K, Sabat R. Interleukin-22: a novel T- and NK-cell derived cytokine that regulates the biology of tissue cells. Cytokine Growth Factor Rev. (2006) 17:367–80. doi: 10.1016/j.cytogfr.2006.09.001 43. Zheng Y, Valdez PA, Danilenko DM, Hu Y, Sa SM, Gong Q, et al. Interleukin- 22 mediates early host defense against attaching and effacing bacterial pathogens. Nat Med. (2008) 14:282–9. doi: 10.1038/nm1720 44. Zapata W, Rodriguez B, Weber J, Estrada H, Quinones-Mateu M, Zimermman P, et al. Increased levels of human beta-defensins mRNA in sexually HIV-1 exposed but uninfected individuals. Curr HIV Res. (2008) 6:531–8. doi: 10.2174/157016208786501463 45. Zapata W, Aguilar-Jiménez W, Feng Z, Weinberg A, Russo A, Potenza N, et al. Identification of innate immune antiretroviral factors during in vivo and in vitro exposure to HIV-1. Microbes Infect. (2016) 18:211–9. doi: 10.1016/j.micinf.2015.10.009 46. Wang W, Wu F, Cong Z, Liu K, Qin C, Wei Q. The secretion of IL-22 from mucosal NKp44 + NK cells is associated with microbial translocation and virus infection in SIV/SHIV-infected Chinese macaques. J Immunol Res. (2014) 2014:1–13. doi: 10.1155/2014/387950 47. Missé D, Yssel H, Trabattoni D, Oblet C, Lo Caputo S, Mazzotta F, et al. IL-22 Participates in an innate anti-HIV-1 host-resistance network through acute-phase protein induction. J Immunol. (2006) 178:407–15. doi: 10.4049/jimmunol.178.1.407 48. Topham NJ, Hewitt EW. Natural killer cell cytotoxicity: how do they pull the trigger? Immunology (2009) 128:7–15. doi: 10.1111/j.1365-2567.2009.03123.x 49. Elliott JM, Yokoyama WM. Unifying concepts of MHC-dependent natural killer cell education. Trends Immunol. (2011) 32:364–72. doi: 10.1016/j.it.2011.06.001 50. Martin MP, Qi Y, Gao X, Yamada E, Martin JN, Pereyra F, et al. Innate partnership of HLA-B and KIR3DL1 subtypes against HIV-1. Nat Genet. (2007) 39:733–40. doi: 10.1038/ng2035 51. Richard J, Sindhu S, Pham NQ, Belzile JP, Cohen EA. HIV-1 Vpr up-regulates expression of ligands for the activating NKG2D receptor and promotes NK cell-mediated killing. Blood (2010) 115:1354–63. doi: 10.1182/blood-2009-08-237370 52. Bernard NF, Kiani Z, Tremblay-McLean A, Kant SA, Leeks CE, Dupuy FP. Natural Killer (NK) cell education differentially influences HIV antibodydependent NK cell activation and antibody-dependent cellular cytotoxicity. Front Immunol. (2017) 8:1033. doi: 10.3389/fimmu.2017.01033 53. Barouch DH, Alter G, Broge T, Linde C, Ackerman ME, Brown EP, et al. Protective efficacy of adenovirus/protein vaccines against SIV challenges in rhesus monkeys. Science (2015) 349:320–4. doi: 10.1126/science.aab3886 54. Bournazos S, Klein F, Pietzsch J, Seaman MS, Nussenzweig MC, Ravetch JV. Broadly Neutralizing anti-HIV-1 antibodies require Fc effector functions for in vivo activity. Cell (2014) 158:1243–53. doi: 10.1016/j.cell.2014.08.023 55. DiLillo DJ, Tan GS, Palese P, V Ravetch J. Broadly neutralizing hemagglutinin stalk–specific antibodies require FcgR interactions for protection against influenza virus in vivo. Nat Med. (2014) 20:143–51. doi: 10.1038/ nm.3443 56. Chung AW, Kumar MP, Arnold KB, Yu WH, Schoen MK, Dunphy LJ, et al. Dissecting polyclonal vaccine-induced humoral immunity against hiv using systems serology. Cell (2015) 163:988–98. doi: 10.1016/j.cell.2015.10.027 57. Ackerman ME, Mikhailova A, Brown EP, Dowell KG, Walker BD, Bailey- 57. Ackerman ME, Mikhailova A, Brown EP, Dowell KG, Walker BD, Bailey- Kellogg C, et al. Polyfunctional HIV-specific antibody responses are associated with spontaneous HIV control. PLOS Pathog. (2016) 12:e1005315. doi: 10.1371/journal.ppat.1005315 58. Giese S,MarshM. Tetherin can restrict cell-free and cell-cell transmission of HIV fromprimary macrophages to T Cells. PLoS Pathog (2014) 10:e1004189. doi: 10.1371/journal.ppat.1004189 59. Arias JF, Heyer LN, von Bredow B,Weisgrau KL, Moldt B, Burton DR, et al. Tetherin antagonism by Vpu protects HIV-infected cells from antibodydependent cell-mediated cytotoxicity, Proc Natl Acad Sci USA. (2014) 111:6425–30. doi: 10.1073/pnas.1321507111 60. Borg C, Jalil A, Laderach D, Maruyama K, Wakasugi H, Charrier S, et al. NK cell activation by dendritic cells (DCs) requires the formation of a synapse leading to IL-12 polarization in DCs, Blood (2004) 104:3267–75. doi: 10.1182/blood-2004-01-0380 61. Gerosa F, Baldani-Guerra B, Nisii C, Marchesini V, Carra G, Trinchieri G. Reciprocal activating interaction between natural killer cells and dendritic cells. J Exp Med. (2002) 195:327–33. doi: 10.1084/jem.20010938 62. Ferlazzo G, TsangML,Moretta L,Melioli G, Steinman RM,Münz C. Human dendritic cells activate resting natural killer (NK) cells and are recognized via the NKp30 receptor by activated NK cells. J ExpMed. (2002) 195:343–51. doi: 10.1084/JEM.20011149 63. Ferlazzo G, Moretta L. Dendritic cell editing by natural killer cells. Crit Rev Oncog. (2014) 19:67–75. doi: 10.1615/CritRevOncog.2014010827 64. Wilder JA, Koh CY, Yuan D. The role of NK cells during in vivo antigenspecific antibody responses. J Immunol. (1996) 156:146–52. 65. Krebs P, Barnes MJ, Lampe K, Whitley K, Bahjat KS, Beutler B, et al. NK cell-mediated killing of target cells triggers robust antigen-specific T cell-mediated and humoral responses. Blood (2009) 113:6593–602. doi: 10.1182/blood-2009-01-201467 66. Perreau M, Savoye AL, De Crignis E, Corpataux JM, Cubas R, Haddad EK, et al. Follicular helper T cells serve as the major CD4 T cell compartment for HIV-1 infection, replication, and production. J Exp Med. (2013) 210:143–56. doi: 10.1084/jem.20121932 67. Huot N, Jacquelin B, Garcia-Tellez T, Rascle P, Ploquin MJ, Madec Y, et al. Natural killer cells migrate into and control simian immunodeficiency virus replication in lymph node follicles in African green monkeys. Nat Med. (2017) 23:1277–86. doi: 10.1038/nm.4421 68. Huot N, Bosinger SE, Paiardini M, Reeves RK, Müller-Trutwin M. Lymph node cellular and viral dynamics in natural hosts and impact for HIV cure strategies. Front Immunol. (2018) 9:780. doi: 10.3389/fimmu.2018.00780 69. Scully E, Alter G. NK Cells in HIV Disease. Curr HIV/AIDS Rep. (2016) 13:85–94. doi: 10.1007/s11904-016-0310-3 70. Michel T, Poli A, Cuapio A, Briquemont B, Iserentant G, Ollert M, et al. Human CD56bright NK cells: an update. J Immunol. (2016) 196:2923–31. doi: 10.4049/jimmunol.1502570 71. Taborda NA, Hernández JC, Montoya CJ, Rugeles MT. Las células natural killer y su papel en la respuesta inmunitaria durante la infección por el virus de la inmunodeficiencia humana tipo-1. Inmunología (2014) 33:11–20. doi: 10.1016/j.inmuno.2013.11.002 72. Moretta A, Marcenaro E, Parolini S, Ferlazzo G, Moretta L. NK cells at the interface between innate and adaptive immunity. Cell Death Differ. (2008) 15:226–33. doi: 10.1038/sj.cdd.4402170 73. Moretta L. Dissecting CD56dim human NK cells. Blood (2010) 116:3689–91. doi: 10.1182/blood-2010-09-303057 74. Alter G, Teigen N, Davis BT, Addo MM, Suscovich TJ, Waring MT, et al. Sequential deregulation of NK cell subset distribution and function starting in acute HIV-1 infection. Blood (2005) 106:3366–9. doi: 10.1182/blood-2005-03-1100 75. Hong HS, Ahmad F, Eberhard JM, Bhatnagar N, Bollmann BA, Keudel P, Ballmaier M, et al. Loss of CCR7 Expression on CD56bright NK Cells Is associated with a CD56dimCD16+ NK cell-like phenotype and correlates with HIV viral load. PLoS ONE (2012) 7:e44820. doi: 10.1371/journal.pone.0044820 76. Bhardwaj S, Ahmad F, Wedemeyer H, Cornberg M, Schulze zur Wiesch J, van Lunzen J, et al. Increased CD56bright NK cells in HIV-HCV co-infection and HCV mono-infection are associated with distinctive alterations of their phenotype. Virol J. (2016) 13:67. doi: 10.1186/s12985-016-0507-5 77. Hong HS, Eberhard JM, Keudel P, Bollmann BA, Ballmaier M, Bhatnagar N, et al. HIV infection is associated with a preferential decline in lessdifferentiated CD56dim CD16+ NK cells. J. Virol. (2010) 84:1183–8. doi: 10.1128/JVI.01675-09 78. Lopez-Vergès S, Milush JM, Pandey S, York VA, Arakawa-Hoyt J, Pircher H, et al. CD57 defines a functionally distinct population of mature NK cells in the human CD56dimCD16+ NK-cell subset. Blood (2010) 116:3865–74. doi: 10.1182/blood-2010-04-282301 79. Milush JM, López-Vergès S, York VA, Deeks SG, Martin JN, Hecht FM, et al. CD56negCD16+ NK cells are activated mature NK cells with impaired effector function during HIV-1 infection Retrovirology (2013) 10:158. doi: 10.1186/1742-4690-10-158 80. Gonzalez VD, Falconer K, Bjorkstrom NK, Blom KG, Weiland O, Ljunggren G, et al. Expansion of functionally skewed CD56-negative NK cells in chronic hepatitis c virus infection: correlation with outcome of pegylated IFN- and ribavirin treatment. J Immunol. (2009) 183:6612–8. doi: 10.4049/jimmunol.0901437 81. Shao JY, Yin WW, Zhang QF, Liu Q, Peng ML, Hu HD,et al. Siglec- 7 defines a highly functional natural killer cell subset and inhibits cellmediated activities. Scand J Immunol. (2016) 84:182–90. doi: 10.1111/sji. 12455 82. Brunetta E, Fogli M, Varchetta S, Bozzo L, Hudspeth KL, Marcenaro E, Moretta A, et al. The decreased expression of Siglec-7 represents an early marker of dysfunctional natural killer-cell subsets associated with high levels of HIV-1 viremia. Blood (2009) 114:3822–30. doi: 10.1182/blood-2009-06-226332 83. Ndhlovu LC, Lopez-Verges S, Barbour JD, Jones RB, Jha AR, Long BR, et al. Tim-3 marks human natural killer cell maturation and suppresses cell-mediated cytotoxicity. Blood (2012) 119:3734–43. doi: 10.1182/blood-2011-11-392951 84. Jost S, Moreno-Nieves U, Garcia-Beltran W, Rands K. Dysregulated Tim-3 expression on natural killer cells is associated with increased Galectin-9 levels in HIV-1 infection. Retrovirology (2013) 10:74. doi: 10.1186/1742-4690-10-74 85. Schafer JL, Li H, Evans TI, Estes JD, Reeves RK. Accumulation of cytotoxic CD16+ NK cells in simian immunodeficiency virus-infected lymph nodes associated with in situ differentiation and functional anergy. J Virol. (2015) 89:6887–94. doi: 10.1128/JVI.00660-15 86. Reeves RK, Rajakumar PA, Evans TI, Connole M, Gillis J, Wong FE, et al. Gut inflammation and indoleamine deoxygenase inhibit IL-17 production and promote cytotoxic potential in NKp44+ mucosal NK cells during SIV infection. Blood (2011)118:3321–30. doi: 10.1182/blood-2011-04- 347260 87. Xu H, Wang X, Liu DX, Moroney-Rasmussen T, Lackner AA, Veazey RS. IL-17-producing innate lymphoid cells are restricted to mucosal tissues and are depleted in SIV-infected macaques. Mucosal Immunol. (2012) 5:658–69. doi: 10.1038/mi.2012.39 88. Körner C, Altfeld M. Role of KIR3DS1 in human diseases. Front Immunol. (2012) 3:326. doi: 10.3389/fimmu.2012.00326 89. Habegger de Sorrentino A, Sinchi JL, Marinic K, López R, Iliovich E. KIRHLA- A and B alleles of the Bw4 epitope against HIV infection in discordant heterosexual couples in Chaco Argentina. Immunology (2013) 140:273–9. doi: 10.1111/imm.12137 90. Jackson E, Zhang CX, Kiani Z, Lisovsky I, Tallon B, Del Corpo A, et al. HIV exposed seronegative (HESN) compared to HIV infected individuals have higher frequencies of telomeric Killer Immunoglobulinlike Receptor (KIR) B motifs; Contribution of KIR B motif encoded genes to NK cell responsiveness. PLoS ONE (2017) 12:e0185160. doi: 10.1371/journal.pone.0185160 91. Carr WH, Rosen DB, Arase H, Nixon DF, Michaelsson J, Lanier LL. Cutting edge: KIR3DS1, a gene implicated in resistance to progression to AIDS, encodes a DAP12-associated receptor expressed on NK cells that triggers NK cell activation 1. J Immunol. (2007) 178:647–51. doi: 10.4049/jimmunol.178.2.647 92. Martin MP, Gao X, Lee JH, Nelson GW, Detels R, Goedert JJ, et al. Epistatic interaction between KIR3DS1 and HLA-B delays the progression to AIDS. Nat Genet. (2002) 31:429–34. doi: 10.1038/ng934 93. Lisovsky I, Isitman G, Song R, DaFonseca S, Tremblay-McLean A, Lebouché B, et al. A higher frequency ofNKG2A + than ofNKG2A − NK cells responds to autologous HIV-infected CD4 cells irrespective of whether or not they coexpress KIR3DL1. J Virol. (2015) 89:9909–19. doi: 10.1128/JVI.01546-15 94. O’Leary JG, Goodarzi M, Drayton DL, von Andrian UH. T cell– and B cell–independent adaptive immunity mediated by natural killer cells. Nat Immunol. (2006) 7:507–16. doi: 10.1038/ni1332 95. Björkström NK, Riese P, Heuts F, Andersson S, Fauriat C, Ivarsson MA, et al. Expression patterns of NKG2A, KIR, and CD57 define a process of CD56dim NK-cell differentiation uncoupled from NK-cell education. Blood (2010) 116:3853–64. doi: 10.1182/blood-2010-04-281675 96. Holder K, Comeau E, Grant M. Origins of natural killer cell memory: special creation or adaptive evolution. Immunology (2018) 154:38–49. doi: 10.1111/imm.12898 97. Lopez-Vergès S, Milush JM, Schwartz BS, Pando MJ, Jarjoura J, York VA, et al. Expansion of a unique CD57+NKG2Chi natural killer cell subset during acute human cytomegalovirus infection. Proc Natl Acad Sci USA. (2011) 108:14725–32. doi: 10.1073/pnas.1110900108 98. Paust S, Gill HS,Wang Z, Flynn MP, Moseman EA, Senman B, et al. Critical role for the chemokine receptor CXCR6 in NK cell–mediated antigenspecific memory of haptens and viruses. Nat Immunol. (2010) 11:1127–35. doi: 10.1038/ni.1953 99. Venkatasubramanian S, Cheekatla S, Paidipally P, Tripathi D, Welch E, Tvinnereim AR, et al. IL-21-dependent expansion of memory-like NK cells enhances protective immune responses againstMycobacteriumtuberculosis. Mucosal Immunol. (2017) 10:1031–42. doi: 10.1038/mi.2016.105 100. Reeves RK, Li H, Jost S, Blass E, Li H, Schafer JL, et al. Antigen-specific NK cell memory in rhesus macaques. Nat Immunol. (2015) 16:927–32. doi: 10.1038/ni.3227 101. Lima JF, Oliveira MS, Pereira NZ, Mitsunari GE, Duarte JS, Sato MN. Distinct natural killer cells in HIV-exposed seronegative subjects with effector cytotoxic CD56dim and CD56bright cells and memory-like CD57+NKG2C+CD56dim Cells. J Acquir Immune Defic Syndr. (2014) 67:463–71. doi: 10.1097/QAI.0000000000000350 102. Gondois-Rey F, Chéret A, Granjeaud S,Mallet F, Bidaut G, Lécuroux C, et al. NKG2C+memory-like NK cells contribute to the control of HIV viremia during primary infection: Optiprim-ANRS 147. Clin Transl Immunol. (2017) 6:e150. doi: 10.1038/cti.2017.22 103. Anderson DJ, Politch JA, Nadolski AM, Blaskewicz CD, Pudney J, Mayer KH. Targeting trojan horse leukocytes for HIV prevention. AIDS (2010) 24:163–87. doi: 10.1097/QAD.0b013e32833424c8 104. Childs RW, Carlsten M. Therapeutic approaches to enhance natural killer cell cytotoxicity against cancer: the force awakens. Nat Rev Drug Discov. (2015) 14:487–98. doi: 10.1038/nrd4506 105. Bergamaschi C, Kulkarni V, Rosati M, Alicea C, Jalah R, Chen S, et al. Intramuscular delivery of heterodimeric IL-15 DNA in macaques produces systemic levels of bioactive cytokine inducing proliferation of NK and T cells. Gene Ther. (2015) 2284:76–86. doi: 10.1038/gt. 2014.84 106. Conlon KC, Lugli E, Welles HC, Rosenberg SA, Fojo AT, Morris JC, et al. Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer. J Clin Oncol. (2015) 33:74–82. doi: 10.1200/JCO.2014.57.3329 107. Garrido C, Abad-Fernandez M, Tuyishime M, Pollara JJ, Ferrari G, Soriano- Sarabia N, Margolis DM. Interleukin-15-stimulated natural killer cells clear HIV-1-infected cells following latency reversal ex vivo. J Virol. (2018) 92:JVI.00235-18. doi: 10.1128/JVI.00235-18 108. Romee R, Rosario M, Berrien-Elliott MM, Wagner JA, Jewell BA, Schappe T, et al. Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia. Sci Transl Med. (2016) 8:357ra123. doi: 10.1126/scitranslmed.aaf2341 109. Cummings JS, Moreno-Nieves UY, Arnold V, Gilbert A, Yarbrough K, Didier C, et al. ANRS HIV Vaccine Network (AHVN), Natural killer cell responses to dendritic cells infected by the ANRS HIV-1 vaccine candidate, MVA HIV. Vaccine (2014) 32:5577–84. doi: 10.1016/j.vaccine.2014. 07.094 110. Ahmad R, Sindhu ST, Toma E, Morisset R, Vincelette J, Menezes J, Ahmad A. Evidence for a correlation between antibody-dependent cellular cytotoxicity-mediating anti-HIV-1 antibodies and prognostic predictors of HIV infection. J Clin Immunol. (2001) 21:227–33. doi: 10.1023/A:1011087 132180 111. Milligan CB, Richardson AA, John-Stewart G, Nduati R, Overbaugh J, John-Stewart G. Passively Acquired Antibody-Dependent Cellular Cytotoxicity (ADCC) activity in HIV-infected infants is associated with reduced mortality. Cell Host Microbe (2015) 17:500–6. doi: 10.1016/j.chom.2015.03.002 112. Lu L, Murakowski DK, Bournazos S, Schoofs T, Sarkar D, Halper- Stromberg A, et al. Enhanced clearance of HIV-1-infected cells by broadly neutralizing antibodies against HIV-1 in vivo. Science (2016) 352:1001–4. doi: 10.1126/science.aaf1279 113. Gómez-Román VR, Patterson LJ, Venzon D, Liewehr D, Aldrich K, Florese R, et al. Vaccine-elicited antibodies mediate antibody-dependent cellular cytotoxicity correlated with significantly reduced acute viremia in rhesus macaques challenged with SIVmac251. J Immunol. (2005) 174:2185–9. doi: 10.4049/jimmunol.174.4.2185 114. Davis ZB, Lenvik T, Hansen L, Felices M, Cooley S, Vallera D, et al. A Novel HIV envelope Bi-specific killer engager enhances natural killer cell mediated ADCC responses against HIV-infected cells. Blood (2016) 128: 2517. 115. Flynn NM, Forthal DN, Harro CD, Judson FN, Mayer KH, Para MF, et al. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J Infect Dis. (2005) 191:654–65. doi: 10.1086/ 428404 116. PitisuttithumP, Gilbert P, GurwithM, HeywardW,MartinM, van Griensven F, et al. Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J Infect Dis. (2006) 194:1661–71. doi: 10.1086/508748 117. Karnasuta C, Paris RM, Cox JH, Nitayaphan S, Pitisuttithum P, Thongcharoen P, et al. Thai AIDS Vaccine Evaluation Group, Thailand, Antibody-dependent cell-mediated cytotoxic responses in participants enrolled in a phase I/II ALVAC-HIV/AIDSVAXR B/E prime-boost HIV-1 vaccine trial in Thailand. Vaccine (2005) 23:2522–9. doi: 10.1016/j.vaccine.2004.10.028 118. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R, et al. MOPH-TAVEG Investigators, Vaccination with ALVAC and AIDSVAX to Prevent HIV-1 Infection in Thailand. N Engl J Med. (2009) 361:2209–2220. doi: 10.1056/NEJMoa0908492 119. Haynes BF, Gilbert PB,McElrathMJ, Zolla-Pazner S, Tomaras GD, AlamSM, et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med. (2012) 366:1275–86. doi: 10.1056/NEJMoa1113425 120. Yates NL, Liao HX, Fong Y, DeCamp A, Vandergrift NA, Williams WT. Vaccine-induced Env V1-V2 IgG3 correlates with lower HIV-1 infection risk and declines soon after vaccination. Sci Transl Med. (2014) 6:228ra39. doi: 10.1126/scitranslmed.3007730 121. Callaway E. Clues emerge to explain first successful HIV vaccine trial. Nature (2011). doi: 10.1038/news.2011.541 122. Bradley T, Pollara J, Santra S, Vandergrift N, Pittala S, Bailey-Kellogg C, et al. Pentavalent HIV-1 vaccine protects against simian-human immunodeficiency virus challenge. Nat Commun. (2017) 8:15711. doi: 10.1038/ncomms15711 123. Glienke W, Esser R, Priesner C, Suerth JD, Schambach A, Wels WS, et al. Advantages and applications of CAR-expressing natural killer cells. Front Pharmacol. (2015) 6:21. doi: 10.3389/fphar.2015.00021 124. Liu D, Tian S, Zhang K, Xiong W, Michel Lubaki N, Chen Z, et al. Chimeric antigen receptor (CAR)-modified natural killer cell-based immunotherapy and immunological synapse formation in cancer and HIV. Protein Cell (2017) 8:861–77. doi: 10.1007/s13238-017-0415-5 125. Zhen A, Kamata M, Rezek V, Rick J, Levin B, Kasparian S, et al. HIV-specific immunity derived from chimeric antigen receptor-engineered stem cells. Mol Ther. (2015) 23:1358–67. doi: 10.1038/mt.2015.102 natural killer cells HIV-1 HIV resistance HIV vaccine Memory NK cells natural killer cells HIV-1 HIV resistance HIV vaccine Memory NK cells NK Cells in HIV-1 Infection: From Basic Science to Vaccine Strategies Artículo http://purl.org/coar/resource_type/c_6501 http://purl.org/coar/version/c_970fb48d4fbd8a85 info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion Atribución info:eu-repo/semantics/openAccess http://purl.org/coar/access_right/c_abf2 Publicationrestricted